Anti breast cancer market to 40 billion! The growth rate of top 10 brand drugs exceeds 20%

Source: minenet 2018-04-08 with the overall advancement of human research on tumor biology, the treatment of tumor has evolved from simple surgical treatment to comprehensive treatment, including antibody drugs, small molecule targeted drugs, traditional chemotherapy, endocrine therapy, traditional Chinese medicine treatment and immunotherapy of recent years Especially in the field of breast cancer treatment, aiming at the difference of expression of human epidermal growth factor type Ⅱ receptor (HER2) in different ages and on the cell surface, various treatment schemes further improve the survival rate of patients With the rapid growth of top5 in the world, new products are eager to try in the field of breast cancer drug treatment in the world Roche's monoclonal antibody Herceptin (Herceptin, trastuzumab) ranks first and leads the whole market According to Roche's annual report and the world's top 100 list of clinical drugs, in 2017, the global Herceptin sales reached $7.534 billion In 2017, the top 5 breast cancer drugs in the world are trastuzumab, ibrance, patozumab, protein paclitaxel and kadcyla The global sales volume of top 5 anti breast cancer drugs reached US $15.093 billion, an increase of 15.46% over 2016 (see Table 1) In addition, new varieties of global anti breast cancer drug R & D pipeline are also emerging In 2017, the U.S FDA approved three new molecular entities of anti breast cancer More than 30 breast cancer drugs are competing in China After reviewing the leading market of breast cancer drugs in the world, we can see the domestic market pattern With the development of China's medical security system reform, the level of domestic drug use has been greatly improved The best-selling drugs in the medical market have been the representative varieties with good efficacy and less side effects With the release of the 2017 edition of the national basic medical insurance drug catalog, the pharmaceutical market will gradually enter a period of reshaping the pattern In the new version of the national medical insurance catalogue, the anti-tumor drugs are further classified into seven sub categories, including alkylating agents, anti metabolism drugs, plant alkaloids and other natural drugs, cytotoxic antibiotics and related drugs, other anti-tumor drugs, endocrine therapy drugs and anti-tumor drugs After the success of a new round of drug price negotiations, 25 new drugs and new dosage forms of bioengineering drugs, small molecule targeted drugs and chemical drugs were added to the new medical insurance catalogue in 2017 Among them, trastuzumab, lapatinib, apatinib, erlotinib, sorafenib, fluvectin, etc., which are used to treat breast cancer, are newly added In addition, there are more than 30 drugs in total, such as paclitaxel, docetaxel, capecitabine, etc., which are used to treat breast cancer 2018 China's incidence rate of breast cancer drugs will reach 40 billion yuan The incidence rate of five major cancers in the world is breast cancer, cervical cancer, endometrial cancer, ovarian cancer and uterine fibroids Among them, breast cancer is the leading cause of female malignancies With the promotion and application of new anti breast cancer drugs, the survival rate of patients gradually increased, which also led to the growth of related markets In 2016, the overall scale of breast cancer drugs in China has exceeded 32 billion yuan, an increase of 11.67% over 2015 It is predicted that the market scale of breast cancer drugs in 2018 will reach 40 billion yuan The ten strong domestic TOP10 varieties increased by 12.10% In the past 30 years, China has about 2 million 600 thousand cancer patients per year The incidence rate of cancer is increasing under the influence of many factors, such as the ecological environment, environmental pollution, dietary pattern changes and survival pressure So far, the treatment of breast cancer is surgery combined with chemotherapy and radiotherapy With the deepening of people's understanding of cancer, new targeted drugs are emerging, and patients have more choices According to the data of mienei.com, in the first three quarters of 2017, the amount of anti-tumor and immunomodulator drugs used in public hospitals in key cities in China was 19.03 billion yuan, which is predicted to reach 26.6 billion yuan in 2017, an increase of 11.74% over the previous year Among them, 58.50% were antitumor drugs, 9.51% were endocrine drugs, 22.34% were immunostimulants and 9.65% were immunosuppressants Forecast data shows that in 2017, the amount of top 10 anti breast cancer drugs used in public hospitals in key cities in China was 5.67 billion yuan, an increase rate of 12.10% over the previous year The top 10 drugs are paclitaxel, docetaxel, trastuzumab, capecitabine, gemcitabine, epirubicin, pirarubicin, goserellin, letrozole and fluvectin In 2017, the market concentration of top 10 anti breast cancer drugs in public hospitals in key cities in China was relatively high, and Paclitaxel injection ranked first It is worth mentioning that trastuzumab has entered the third place from the fourth in 2015 Under the favorable factors of entering the national medical insurance catalog, it is predicted that trastuzumab will become one of the fast-growing varieties in 2018 According to the sales data of antineoplastic and immunomodulator drugs of public hospitals in key cities of China from January to March 2017, the growth rate of domestic top 10 brand drugs is predicted to be 4.405 billion yuan in 2017, an increase of 17.55% over the previous year In 2017, in the market of public hospitals in key cities in China, the market share of paclitaxel liposome "Lipitor" of Nanjing green leaf ranked first in the anti breast cancer brand drugs, with an increase rate of 20.14% Paclitaxel is a broad-spectrum anti-tumor drug Its unique microtubule stabilizing effect is widely used in chemotherapy of many common malignant tumors After the advent of paclitaxel liposomes, a breakthrough has been made in the treatment The second largest brand is Roche's Herceptin, with a year-on-year growth rate of 28.36% in 2017 compared with 2016 Trastuzumab is a kind of humanized monoclonal antibody derived from recombinant DNA It is a representative anti-tumor targeting antibody drug, which is used in the treatment of advanced breast cancer At present, the European Union has approved the combination of Herceptin and docetaxel as the first-line treatment of human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer In addition to Lipitor and Herceptin, the growth rate of AstraZeneca's noread is 24.84%, and that of Sanofi's tersotti is 22.22% According to the change trend of market share of all brands, the growth trend of top 10 brands of breast cancer drugs in China is obvious in 2018, and Lipitor of Nanjing green leaf, Herceptin of Roche and Xeloda of Roche will continue to grow In addition, the market share of the group will increase after it enters the medical insurance catalogue.